The Medical Letter on Drugs and Therapeutics
Dichlorphenamide (Keveyis) for Periodic Paralysis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Dichlorphenamide (Keveyis – Taro), an oral carbonic anhydrase inhibitor, has been approved by the FDA for treatment of primary hypokalemic and hyperkalemic periodic paralysis and related variants. Dichlorphenamide is the first drug to be approved in the US for this indication. It was approved as Daranide in 1958 for treatment of glaucoma, but had not been marketed since 2002.

THE DISEASE — Periodic paralysis is a rare hereditary disorder caused by sodium or calcium channel defects in skeletal muscle. The disease is characterized by episodes of muscle weakness, paralysis, and often hypo- or hyperkalemia. Acetazolamide (Diamox, and generics), another oral carbonic anhydrase inhibitor, has been used off-label for treatment of periodic paralysis for years; in an observational study, 34 of 74 patients with hypokalemic periodic paralysis (46%) benefited from acetazolamide ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Dichlorphenamide (Keveyis) for Periodic Paralysis
Article code: 1492d
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian